anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the dental prosthetic appliance adequate for tooth restoration by means of crowns, bridges, etc., by constituting the compsn. of an internal layer part after sintering of specific conductive ceramics, dental porcelain and specific metals and constituting an outer layer part of dental porcelain. CONSTITUTION:The dental prosthetic appliance adequate for tooth restoration by means of crowns, bridges, etc., is constituted of the inside layer part and the outside layer part. The inside layer part is a sintered body and the compsn. after the sintering consists of 40 to 95wt.% one or >=2 kinds of the conductive ceramics selected from nitride ceramics, boride ceramics and carbide ceramics having <=10<-1>OMEGA.cm electrical resistivity, and 5 to 60wt.% dental porcelain and/or one or >=2 kinds of the metals selected from Ti, Zr, Au, Pt, Pd, Ag, In, and Sn. Further, the outside layer part is formed of the dental porcelain.
A human IL-1R1 gene, a protein, a homodimeric protein, and the use. A K131E mutation of a human IL-1R1 (Interleukin 1 Receptor Type 1) protein is identified for the first time in a collected library of patients with autoinflammatory diseases by means of a whole exome capture technology, a next-generation sequencing technology and an auxiliary genetic diagnosis algorithm. It is proved that the K131E mutation inhibits the binding of the IL-1R1 protein to antagonist IL-1Ra thereof, but does not change the binding of the IL-1R1 protein to agonist IL-1β thereof. On the basis of the above-mentioned discovery, further provided is a homodimeric protein capable of specifically binding to IL-1β and blocking the function thereof without binding to IL-1Ra. The homodimeric protein is assembled with an IL-1R1 extracellular segment portion containing a K131E site-directed mutation, and the portion is fused to an Fc fragment of human IgG-1. A protein polypeptide with a rare mutation can not only specifically block the function of the inflammatory activator IL-1β, but can also retain the function of the inflammatory antagonist IL-1Ra, thereby accelerating the speed of inhibiting inflammation.
The sham group will receive 3 sham treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT.
Patients receive bevacizumab as in Arm I and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Muscle activity, as a possible fundamental cause of functional limitation, has been extensively investigated in knee osteoarthritis (KOA). Interestingly, studies concentrated mainly on investigation of muscle activity during dynamic movements and different functional tests. Moznuzzaman et al displayed greater muscle activation during sitting to standing test (STS) and standing to sitting test in KOA patients compared to healthy participants. Interestingly, some studies investigated muscle activation standing up from a knee-height seat during STS and illustrated a greater muscle activation amongst KOA patients compared to healthy controls. Moreover, Amer et al found greater muscle activation while performing STS from a lower height seat compared to a knee-height seat amongst women and men patients with uni/bilateral KOA. These findings might be of interest due to compensatory mechanisms observed by female patients during STS transition increases loading on the joint surfaces and consequently leading to progression of KOA. Furthermore, different studies also presented gender-differences of muscle activation during different weight-bearing tasks (gait, STS, stair ascend/descend, and squat) amongst patients with KOA and healthy control. Interestingly, both studies showed women with KOA representing higher muscle activation compared to men. Therefore, an analytical comparative study might be useful for identification of gender-differences in muscle activation amongst patients with KOA.

Investigation of static muscle activity during functional movements is very rare in KOA. Zhang et al investigated muscle activation after single whole body vibration trial in standing position at 0°, 30° and 60° static knee flexion angles amongst women with KOA. Authors found that muscle activation in 60° was greater compared to 30°, and it was also greater in 30° compared to 0°. Based on our literature search, no further study examined muscle activity in static knee flexion in KOA. However, investigating static knee flexion might be useful as it could be related to different knee moments in KOA.
Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
Clonal hematopoiesis (CH) arises when hematopoietic stem cells (HSCs) acquire mutations, most frequently in the DNMT3A and TET2 genes, conferring a competitive advantage through mechanisms that remain unclear. To gain insight into how CH mutations enable gradual clonal expansion, we used single-cell multi-omics with high-fidelity genotyping on human CH bone marrow (BM) samples. Most of the selective advantage of mutant cells occurs within HSCs. DNMT3A- and TET2-mutant clones expand further in early progenitors, while TET2 mutations accelerate myeloid maturation in a dose-dependent manner. Unexpectedly, both mutant and non-mutant HSCs from CH samples are enriched for inflammatory and aging transcriptomic signatures, compared with HSCs from non-CH samples, revealing a non-cell-autonomous effect. However, DNMT3A- and TET2-mutant HSCs have an attenuated inflammatory response relative to wild-type HSCs within the same sample. Our data support a model whereby CH clones are gradually selected because they are resistant to the deleterious impact of inflammation and aging.
The shoulder mobilization group. Participants in this group received conventional physiotherapy and shoulder joint mobilization techniques. Number of the participants were 15.
PURPOSE: An examination room PC base method for connecting between hospital and clinic EMR system and an internet-based private health register account is provided to supply a PHR account screen automatically connected in the EMR system by effectively connecting the EMR system and the PHR system. CONSTITUTION: A PHR access module extracts medical record number data of the presently activated patient(S20). It confirms whether the hospital code is matched with the medical record number(S30). It confirms whether the PHR ID is matched with the medical record number(S50). The PHR account access authorization code of the patient is transmitted. The PHR account access authentication procedure is operated.
1,137,667. Wax-like solid materials. YAMANOUCHI SEIYAKU K.K. 11 March, 1966 [5 July, 1965], No. 10882/66. Heading A5B. A single phase wax-like solid material useful as a suppository or ointment base comprises 1 part by wt. of sorbitol and a total of 0.3 to 4 parts by wt. of one or more of the hydroxy compounds glycerine and alkylenediols having from 2 to 6 carbon atoms, e.g. 1,2-ethanediol, 1,2-propanediol, 1,4-butanediol and 2,5-hexanediol. The solid material may be in admixture with one or more substances which modify the rheological properties thereof without distroying its waxlike character, e.g. water, polyoxyalkylenes such as polyethylene and polypropylene glycols, polyoxyethylene alkyl-ether, alkylaryl-ether, alkyl-ester and sorbitan alkyl-ester and a block polymer of polyethylene glycol and polypropylene glycol; polyvinyl pyrrolidone cellulose acetate and acetate phthalate, hydroxypropoxycellulose and methyl and ethyl cellulose, specific examples including polyoxyethylene dodecyl-ether. When the hydroxycompound is glycerine, a solid purgative is obtained. Examples of suppositories containing phenol, chloramphenicol and extractum scopoliae as active ingredients are given.
To determine the kinetics of hepatitis E virus (HEV) in asymptomatic persons and to evaluate viral load doubling time and half-life, we retrospectively tested samples retained from 32 HEV RNA-positive asymptomatic blood donors in Germany. Close-meshed monitoring of viral load and seroconversion in intervals of ≈4 days provided more information about the kinetics of asymptomatic HEV infections. We determined that a typical median infection began with PCR-detectable viremia at 36 days and a maximum viral load of 2.0 × 104 IU/mL. Viremia doubled in 2.4 days and had a half-life of 1.6 days. HEV IgM started to rise on about day 33 and peaked on day 36; IgG started to rise on about day 32 and peaked on day 53. Although HEV IgG titers remained stable, IgM titers became undetectable in 40% of donors. Knowledge of the dynamics of HEV viremia is useful for assessing the risk for transfusion-transmitted hepatitis E.
The present invention relates to sedation assessment. In order to facilitate sedation assessment in an environment of an imaging system, a sedation assessment system is provided. The sedation assessment system comprises at least one stimulus generator, a controlling device, at least one sensing device, and a sedation determination device. The controlling device is configured to generate at least one control signal including a first control signal and/or a second control signal. The at least one stimulus generator comprises a remote haptic device configured to induce, from a distance, a haptic sensation at a first impact region on a patient's skin in response to the first control signal. Additionally or alternatively, the at least one stimulus generator comprises a heating and/or cooling device attachable to a second impact region on a patient's skin and configured to heat or cool the second impact region for inducing a pain sensation in response to the second control signal. The at least one sensing device is configured to detect a patient reaction in response to the haptic sensation and/or the pain sensation. The sedation determination device is configured to determine, based on the detected patient reaction, a sedation level of the patient.
The role of phosphodiesterase 5 (Pde5) in obstructive sleep apnea-induced damage remains unclear. Our study aimed to investigate the role of Pde5 in the chronic intermittent hypoxia (CIH) model. C57BL/6J wild-type (WT) mice (n = 48) and Pde5 knockout (Pde5 -/- ) mice (n = 24) were randomly assigned to CIH group and room air group. After 6 weeks, some WT mice (n = 24) in CIH group were given sildenafil or saline gavage for another 4 weeks. Blood pressure was regularly measured during the experiment. Echocardiography was used to estimate cardiac function. We collected organs from each group of mice and measured their physical indicators. Histochemical staining was used to explore the size of cardiomyocyte and fibrosis area of various organs. Cyclic guanosine monophosphate and malondialdehyde concentrations in serum were measured by ELISA assay. Compared with the RA-treated group, the 6-week CIH resulted in a significant increase in blood pressure, altered heart structure, and reduced serum cyclic guanosine monophosphate in WT mice. Pde5 -/- mice and sildenafil intragastric administration significantly reduced systolic blood pressure in CIH condition and attenuated the damage of target organs. In CIH model, we found that the cardiomyocyte size and fibrosis area of heart and kidney significantly reduced in Pde5 -/- groups. Besides, endogenous and exogenous inhibition of Pde5 reduced malondialdehyde level and inflammatory and oxidative stress markers expression in CIH condition. In this study, we found that Pde5 inhibition could reduce blood pressure and alleviate target organ damage in the CIH model, which may be mediated through the oxidative stress pathway.
RATIONALE: Diagnosing cystic fibrosis (CF) pulmonary exacerbations (PEx) in very young people with CF <3 years (VY-PwCF) is challenging because of the frequency of respiratory viral infections in this age group, and there are limited data on the clinical features associated with the diagnosis of PEx in this age group. The goal of this study was to identify clinical features associated with the diagnosis of PEx in VY-PwCF.
METHODS: We reviewed the medical records of VY-PwCF followed at the Children's Hospital of Philadelphia born between 2013 and 2019. We collected data from all encounters with respiratory symptoms. PEx was defined by treatment with oral or intravenous antibiotics. Clinical features of PEx and non-PEx encounters were compared using descriptive statistics, and odds ratios of PEx diagnosis were calculated.
RESULTS: A total of 78 patients were included in the analysis. The mean (SD) number of PEx per patient was 6.17 (5.88). The presence of a wet or nighttime cough and symptoms >3 days in duration were significantly associated with PEx diagnosis (p < .001). In contrast, symptoms such as sore throat or rhinorrhea were not associated with a higher likelihood of PEx.
CONCLUSIONS: The presence of a wet or night-time cough and longer symptom duration are common features of PEx in VY-PwCF, whereas symptoms suggestive of upper respiratory viral infection are not. Our results will be helpful in counseling families of VY-PwCF in the signs and symptoms of PEx and in planning future research in PEx in this age group.
The ReX platform study group will utilize data, collected from the same study sites that were chosen for control study group. A database consisting of at least fifty (50) female and male participants who initiated ribociclib for metastatic breast cancer and signed IRB research consent will be used for ReX study group. This group will include participants who started the recommended ribo dose of 600 mg QD and additional doses, delivered by the ReX technology platform. Physical examinations and laboratory tests will be performed in accordance with routine clinical practice; however, these parameters will not be collected for the study.
Sepsis is characterized as a systemic inflammatory response syndrome resulting from infection, leading to the development of multiple organ dysfunction syndrome. Sepsis-induced cardiomyopathy (SICM) is a frequently encountered condition in clinical settings. Mesenchymal stem cells (MSCs) possess inherent immunomodulatory and anti-inflammatory attributes, rendering them a promising therapeutic approach to reestablish the equilibrium between anti-inflammatory and proinflammatory systems in septic patients. Consequently, MSCs are frequently employed in clinical investigations. In this study, the author established a mouse SICM model through cecal ligation and puncture and administered MSCs through the tail vein. Following successful modeling, the myocardial function and histopathological changes were detected by echocardiography, hematoxylin-eosin staining, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, enzyme-linked immunosorbent assay,, and other experiments. As a result, MSCs demonstrated the ability to enhance myocardial function, promote cardiac tissue repair, suppress inflammatory response, reduce levels of myocardial injury markers, and mitigate oxidative stress. In addition, transcriptome and proteome analyses were conducted. Through differential expression analysis, functional enrichment analysis, and multiomics association analysis, it was revealed that the transcriptional factors nuclear receptor subfamily 1 (NR1D2) and target gene lipocalin 2 (LCN2) played key roles in mediating the effects of MSCs on SICM. JASPAR website and ChIP-qPCR experiment were used to predict and confirm the targeting relationship between them. Subsequent cell coculture experiments and a series of experiments confirmed that MSCs attenuated cardiomyocyte injury by downregulating the expression of NR1D2 and its downstream target gene LCN2. In conclusion, MSCs alleviate mice SICM through inhibiting NR1D2/LCN2 pathway.
Techniques disclosed herein relate to generating and applying subject event timelines for various purposes. In various embodiments, data indicative of medical events associated with a subject may be retrieved from various data sources. Each of the medical events may be associated with a respective timestamp. Based on the medical events and associated timestamps, a timeline data structure associated with the subject may be assembled. The timeline data structure may be analyzed to identify inconsistenc(ies) between medical events associated with the subject. A visual timeline indicative of the medical events may be rendered on a display based on the timeline data structure. Each respective medical event may be represented in the visual timeline by a graphical element. Two or more of the graphical elements that are associated with the medical events for which the inconsistenc(ies) were identified may be visually distinguished.
PURPOSE:To obtain a water in oil type emulsion with good temp. stability and good using property, in preparing the water in oil type emulsion, by containing monoglycerides of pyroglutamic acid in specific base components in a definite ratio. CONSTITUTION:1-20pts.wt. monoglycerides of pyroglutamic acid, 2-20pts.wt. oil agent such as hydrocarbons or the like, 1.5-60pts.wt. polyhydric alcohol having three or more of hydroxyl groups in a molecule such as glycerine or the like and 20-85pts.wt. water are compounded so as to adjust a ratio of an oil phase component and a water phase to 1:3-9, glycerides and the oil agent to 1:0.5-5 and glycerides and the polyhydric alcohol to 1:0.5-9 and, thereby, a water in oil emulsion having a high internal phase ratio is prepared. The resulting emulsion has no problem in stability based on temp. variation as well as is excellent in using property.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have a variety of cardiovascular and renoprotective effects and have been developed as novel agents for the treatment of heart failure. However, the beneficial mechanisms of SGLT2i on cardiac tissue need to be investigated further. In this study, we established a mouse model of acute myocardial infarction (AMI) using coronary artery constriction surgery and investigated the role of dapagliflozin (DAPA) in protecting cardiomyocytes from hypoxic injury induced by AMI. In vitro experiments were done using hypoxic cultured H9c2 ventricular cells to verify this potential mechanism. Expression of the SIRT family and related genes and proteins was verified by qPCR, Western blotting and immunofluorescence staining, and the intrinsic potential mechanism of cardiomyocyte death due to AMI and hypoxia was comprehensively investigated by RNA sequencing. The RNA sequencing results of cardiomyocytes from AMI mice showed that the SIRT family may be mainly involved in the mechanisms of hypoxia-induced cardiomyocyte death. In vitro hypoxia-induced ventricular cells showed the role of dapagliflozin in conferring resistance to hypoxic injury in cardiomyocytes. It showed that SIRT1/3/6 were downregulated in H9c2 cells in a hypoxic environment, and the addition of dapagliflozin significantly increased the gene and protein expression of SIRT1, 3 and 6. We then verified the underlying mechanisms induced by dapagliflozin in hypoxic cardiomyocytes using RNA-seq, and found that dapagliflozin upregulated the hypoxia-induced gene downregulation, which includes ESRRA, EPAS1, AGTRAP, etc., that associated with SIRTs-related and apoptosis-related signaling to prevent H9c2 cell death. This study provides laboratory data for SGLT2i dapagliflozin treatment of AMI and confirms that dapagliflozin can be used to treat hypoxia-induced cellular necrosis in cardiomyocytes, in which SIRT1 and SIRT3 may play an important role. This opens up further opportunities for SGLT2i in the treatment of heart disease.
PURPOSE: A pharmaceutical composition containing auraptene as an active ingredient for promoting angiogenesis is provided to promote angiogenesis by auraptene, and to effectively regenerate tissues through skin flap regeneration, wound and burn healing, and artificial skin transplantation. CONSTITUTION: A pharmaceutical composition for promoting angiogenesis contains 1-10 micromole of auraptene as an active ingredient. Auraptene promotes tissue regeneration. The pharmaceutical composition is used for skin flap regeneration, wound and burn healing, artificial skin transplantation, or preparation of blood vessels for transplantation. A food composition for promoting angiogenesis contains auraptene as an active ingredient. Auraptene promotes angiogenesis. [Reference numerals] (AA) Control group; (BB) Auraptene 1μM; (CC) Auraptene 5μM; (DD) Auraptene 10μM; (EE) Auraptene 40μM
Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
BACKGROUND: The manubrium and body of the sternum are connected by the manubrium-sternum joint (MSJ). In performing the Nuss procedure for pectus excavatum patients, the body of the sternum is elevated as the operator flips correction bars upside down. Theoretically, the presence of the MSJ should allow elevation of the sternum body. However, does the MSJ secure sufficient elevation of the sternum? This study aims to elucidate this clinical question.
METHODS: Seventy-four adult pectus excavatum patients with moderate to serious deformity (with Haller Index being equal to or greater than 5) were included in the study. The MSJ was open in all patients. For 29 patients, the sternum was elevated by only bar flipping (Non-Separation Group); for 45 patients, the sternum was horizontally separated after bar flipping (Separation Group). Whether or not additional elevation for Separation Group patients results from the division was observed, and the degree of the additional elevation was evaluated. Furthermore, 74 patients subjectively evaluated postoperative pain and gave scores with a Visual Analog Scale ranging from 0 (no pain) to 10 (intolerable pain). The VAS scores were compared between the two groups.
RESULTS: In the Separation Group, the sternums of all patients achieved additional elevation from sternum separation. The pain scores were lower for the Separation Group than for the Non-Separation Group.
CONCLUSION: Even when the MSJ is present, horizontal separation enhances the elevation of the sternum. Furthermore, horizontal separation of the sternum reduces postoperative pain.
A robot system with a robot that has a camera, monitor, a microphone and a speaker. A communication link can be established with the robot through a cellular phone. The link may include an audio only communication. Alternatively, the link may include audio and video communication between the cellular phone and the robot. The phone can transmit its resolution to the robot and cause the robot to transmit captured images at the phone resolution. The user can cause the robot to move through input on the cellular phone. For example, the phone may include an accelerometer that senses movement, and movement commands are then sent to the robot to cause a corresponding robot movement. The phone may have a touch screen that can be manipulated by the user to cause robot movement and/or camera zoom.